Table 1.
Patient background.
| Total | Melanoma | NSCLC | HNC | RCC | |
|---|---|---|---|---|---|
| n = 275, (%) | n = 55, (%) | n = 119, (%) | n = 63, (%) | n = 38, (%) | |
| Age (years), median (range) | 68 (16–89) | 70 (16–86) | 68 (39–89) | 66 (42–81) | 69 (52–83) |
| Sex | |||||
| Male | 203 (73.8) | 30 (54.5) | 98 (82.4) | 46 (73.0) | 29 (76.3) |
| Female | 72 (26.2) | 25 (45.5) | 21 (17.6) | 17 (27.0) | 9 (23.7) |
| ECOG PS | |||||
| 0–1 | 251 (91.3) | 53 (96.4) | 108 (90.8) | 56 (88.9) | 34 (89.5) |
| 2 | 24 (8.7) | 2 (3.6) | 11 (9.2) | 7 (11.1) | 4 (10.5) |
| Number of prior regimens | |||||
| 0 | 67 (24.4) | 23 (41.8) | 23 (19.3) | 20 (31.7) | 1 (2.6) |
| 1 | 114 (41.4) | 23 (41.8) | 46 (38.7) | 30 (47.6) | 15 (39.5) |
| ≥ 2 | 94 (34.2) | 9 (16.4) | 50 (42.0) | 13 (20.6) | 22 (57.9) |
| Number of metastatic sites | |||||
| 0 | 24 (8.7) | 2 (3.6) | 4 (3.4) | 18 (28.6) | 0 (−) |
| 1 | 103 (37.5) | 20 (36.4) | 43 (36.1) | 30 (47.6) | 10 (26.3) |
| ≥ 2 | 148 (53.8) | 33 (60.0) | 72 (60.5) | 15 (23.8) | 28 (73.7) |
| Anti-PD-1 antibody | |||||
| Nivolumab | 218 (79.3) | 41 (74.5) | 76 (63.9) | 63 (100) | 38 (100) |
| Pembrolizumab | 57 (20.7) | 14 (25.5) | 43 (36.1) | 0 (−) | 0 (−) |
All patients are Asian.
NSCLC non-small cell lung cancer, HNC head and neck cancer, RCC renal cell carcinoma, ECOG PS Eastern Cooperative Oncology Group performance status, PD-1 programmed cell death-1.